Skip to main content
Top
Published in: Journal of Neural Transmission 12/2017

Open Access 01-12-2017 | High Impact Review in Neuroscience, Neurology or Psychiatry - Review Article

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed

Authors: Nataliya Titova, Pablo Martinez-Martin, Elena Katunina, K. Ray Chaudhuri

Published in: Journal of Neural Transmission | Issue 12/2017

Login to get access

Abstract

Holistic management of Parkinson’s disease, now recognised as a combined motor and nonmotor disorder, remains a key unmet need. Such management needs relatively accurate definition of the various stages of Parkinson’s from early untreated to late palliative as each stage calls for personalised therapies. Management also needs to have a robust knowledge of the progression pattern and clinical heterogeneity of the presentation of Parkinson’s which may manifest in a motor dominant or nonmotor dominant manner. The “advanced” stages of Parkinson’s disease qualify for advanced treatments such as with continuous infusion or stereotactic surgery yet the concept of “advanced Parkinson’s disease” (APD) remains controversial in spite of growing knowledge of the natural history of the motor syndrome of PD. Advanced PD is currently largely defined on the basis of consensus opinion and thus with several caveats. Nonmotor aspects of PD may also reflect advancing course of the disorder, so far not reflected in usual scale based assessments which are largely focussed on motor symptoms. In this paper, we discuss the problems with current definitions of “advanced” PD and also propose the term “complex phase” Parkinson’s disease as an alternative which takes into account a multimodal symptoms and biomarker based approach in addition to patient preference.
Literature
go back to reference Antonini A, Odin P, Kleinman L, Skalicky A, Marshall T, Sail K, Onuk K (2015) Implementing a Delphi panel to improve understanding of patient characteristics of advanced Parkinson’s disease. Mov Disord (Abstract) Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders. San Diego, CA, USA. Poster 1186 Antonini A, Odin P, Kleinman L, Skalicky A, Marshall T, Sail K, Onuk K (2015) Implementing a Delphi panel to improve understanding of patient characteristics of advanced Parkinson’s disease. Mov Disord (Abstract) Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders. San Diego, CA, USA. Poster 1186
go back to reference Antonini A, Schmidt P, Odin P, Kleinman L, Skalicky A, Sail K, Jalundhwala Y, Zamudio J, Onuk K, Fernandez H (2017). Development of a clinician-reported screening tool to identify patients with Parkinson’s disease inadequately controlled on oral medication. In: Presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders, Vancouver, Canada. Mov Disord (Abstract) 32 (suppl 2): Poster 210 Antonini A, Schmidt P, Odin P, Kleinman L, Skalicky A, Sail K, Jalundhwala Y, Zamudio J, Onuk K, Fernandez H (2017). Development of a clinician-reported screening tool to identify patients with Parkinson’s disease inadequately controlled on oral medication. In: Presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders, Vancouver, Canada. Mov Disord (Abstract) 32 (suppl 2): Poster 210
go back to reference Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators PARS (2016) Cognition in individuals at risk for Parkinson’s: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 31(1):86–94. doi:10.1002/mds.26373 CrossRefPubMed Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators PARS (2016) Cognition in individuals at risk for Parkinson’s: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 31(1):86–94. doi:10.​1002/​mds.​26373 CrossRefPubMed
go back to reference Chen H, Zhao EJ, Zhang W, Yi Lu, Rui Liu, Huang X, Ciesielski-Jones AJ, Justice MA, Cousins DS, Peddada S (2015) Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener 4(1):1CrossRefPubMedPubMedCentral Chen H, Zhao EJ, Zhang W, Yi Lu, Rui Liu, Huang X, Ciesielski-Jones AJ, Justice MA, Cousins DS, Peddada S (2015) Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener 4(1):1CrossRefPubMedPubMedCentral
go back to reference Cilia R, Cereda E, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Ruffmann C, Isaias IU, Goldwurm S, Pezzoli G (2015) Parkinson’s disease beyond 20 years. J Neurol Neurosurg Psychiatry 86(8):849–855. doi:10.1136/jnnp-2014-308786 CrossRefPubMed Cilia R, Cereda E, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Ruffmann C, Isaias IU, Goldwurm S, Pezzoli G (2015) Parkinson’s disease beyond 20 years. J Neurol Neurosurg Psychiatry 86(8):849–855. doi:10.​1136/​jnnp-2014-308786 CrossRefPubMed
go back to reference Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 133:535–545CrossRefPubMedPubMedCentral Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 133:535–545CrossRefPubMedPubMedCentral
go back to reference Godinho C, Domingos J, Cunha G, Santos AT, Fernandes RM, Abreu D, Gonçalves N, Matthews H, Isaacs T, Duffen J, Al-Jawad A, Larsen F, Serrano A, Weber P, Thoms A, Sollinger S, Graessner H, Maetzler W, Ferreira JJ (2016) A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease. J Neuroeng Rehabil 13:24. doi:10.1186/s12984-016-0136-7 CrossRefPubMedPubMedCentral Godinho C, Domingos J, Cunha G, Santos AT, Fernandes RM, Abreu D, Gonçalves N, Matthews H, Isaacs T, Duffen J, Al-Jawad A, Larsen F, Serrano A, Weber P, Thoms A, Sollinger S, Graessner H, Maetzler W, Ferreira JJ (2016) A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease. J Neuroeng Rehabil 13:24. doi:10.​1186/​s12984-016-0136-7 CrossRefPubMedPubMedCentral
go back to reference Hassan A, Wu SS, Schmidt P, Simuni T, Giladi N, Miyasaki JM, Bloem BR, Malaty IA, Okun MS (2015) The profile of long-term Parkinson’s disease survivors with 20 years of disease duration and beyond. J Parkinsons Dis 5(2):313–319. doi:10.3233/JPD-140515 CrossRefPubMed Hassan A, Wu SS, Schmidt P, Simuni T, Giladi N, Miyasaki JM, Bloem BR, Malaty IA, Okun MS (2015) The profile of long-term Parkinson’s disease survivors with 20 years of disease duration and beyond. J Parkinsons Dis 5(2):313–319. doi:10.​3233/​JPD-140515 CrossRefPubMed
go back to reference Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190–199CrossRefPubMed Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190–199CrossRefPubMed
go back to reference Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844. doi:10.1002/mds.21956 CrossRefPubMed Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844. doi:10.​1002/​mds.​21956 CrossRefPubMed
go back to reference Korczyn AD (1999) Parkinson’s disease: one disease entity or many? J Neural Transm 1(56):107–111CrossRef Korczyn AD (1999) Parkinson’s disease: one disease entity or many? J Neural Transm 1(56):107–111CrossRef
go back to reference Langston JW (2006) The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59(4):591–596CrossRefPubMed Langston JW (2006) The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59(4):591–596CrossRefPubMed
go back to reference Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Bloem BR, Burn D, Dodel R, Grosset DG, Hipp G, Hu MT, Kasten M, Krüger R, Liepelt-Scarfone I, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Walter U, Wirdefeldt K, Berg D (2016) Aiming for study comparability in Parkinson’s disease: proposal for a modular set of biomarker assessments to be used in longitudinal studies. Front Aging Neurosci 8:121. doi:10.3389/fnagi.2016.00121 CrossRefPubMedPubMedCentral Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Bloem BR, Burn D, Dodel R, Grosset DG, Hipp G, Hu MT, Kasten M, Krüger R, Liepelt-Scarfone I, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Walter U, Wirdefeldt K, Berg D (2016) Aiming for study comparability in Parkinson’s disease: proposal for a modular set of biomarker assessments to be used in longitudinal studies. Front Aging Neurosci 8:121. doi:10.​3389/​fnagi.​2016.​00121 CrossRefPubMedPubMedCentral
go back to reference Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26(3):399–406. doi:10.1002/mds.23462 CrossRefPubMed Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26(3):399–406. doi:10.​1002/​mds.​23462 CrossRefPubMed
go back to reference Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C, DeNoPa Study Group (2016) Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87(2):168–177. doi:10.1212/WNL.0000000000002651 CrossRefPubMedPubMedCentral Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C, DeNoPa Study Group (2016) Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87(2):168–177. doi:10.​1212/​WNL.​0000000000002651​ CrossRefPubMedPubMedCentral
go back to reference Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, Rodriguez M (2008) Functional organization of the basal ganglia: therapeutic implications for Parkinson’s disease. Mov Disord 23(3):S548–S559. doi:10.1002/mds.22062 CrossRefPubMed Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, Rodriguez M (2008) Functional organization of the basal ganglia: therapeutic implications for Parkinson’s disease. Mov Disord 23(3):S548–S559. doi:10.​1002/​mds.​22062 CrossRefPubMed
go back to reference Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W, National Steering Committees (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 21(10):1133–1144. doi:10.1016/j.parkreldis.2015.07.020 CrossRefPubMed Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W, National Steering Committees (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 21(10):1133–1144. doi:10.​1016/​j.​parkreldis.​2015.​07.​020 CrossRefPubMed
go back to reference Pistacchi M, Gioulis M, Sanson F, De Giovannini E, Filippi G, Rossetto F, Marsala SZ (2017) Gait analysis and clinical correlations in early Parkinson’s disease. Funct Neurol 32(1):28–34CrossRefPubMedPubMedCentral Pistacchi M, Gioulis M, Sanson F, De Giovannini E, Filippi G, Rossetto F, Marsala SZ (2017) Gait analysis and clinical correlations in early Parkinson’s disease. Funct Neurol 32(1):28–34CrossRefPubMedPubMedCentral
go back to reference Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 5:229–238PubMedPubMedCentral Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 5:229–238PubMedPubMedCentral
go back to reference Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel W, Dauvilliers Y, Ju YE, Puligheddu M, Sonka K, Pelletier A, Santamaria J, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Unger MM, Carlander B, Fantini ML, Montplaisir JY (2015) Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 77(5):830–839. doi:10.1002/ana.24385 CrossRefPubMed Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel W, Dauvilliers Y, Ju YE, Puligheddu M, Sonka K, Pelletier A, Santamaria J, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Unger MM, Carlander B, Fantini ML, Montplaisir JY (2015) Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 77(5):830–839. doi:10.​1002/​ana.​24385 CrossRefPubMed
go back to reference Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RG, Martinez-Martin P (2013) A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 11(2):e0150130. doi:10.1371/journal.pone.0150130 CrossRef Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RG, Martinez-Martin P (2013) A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 11(2):e0150130. doi:10.​1371/​journal.​pone.​0150130 CrossRef
go back to reference Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19(10):1196–1202CrossRefPubMed Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19(10):1196–1202CrossRefPubMed
go back to reference Takeda A, Baba T, Kikuchi A, Hasegawa T, Sugeno N, Konno M, Miura E, Mori E (2014) Olfactory dysfunction and dementia in Parkinson’s disease. J Parkinsons Dis 4(2):181–187. doi:10.3233/JPD-130277 PubMed Takeda A, Baba T, Kikuchi A, Hasegawa T, Sugeno N, Konno M, Miura E, Mori E (2014) Olfactory dysfunction and dementia in Parkinson’s disease. J Parkinsons Dis 4(2):181–187. doi:10.​3233/​JPD-130277 PubMed
go back to reference Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative Parkinson’s Progression Markers (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 30(7):919–927. doi:10.1002/mds.26170 CrossRefPubMedPubMedCentral Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative Parkinson’s Progression Markers (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 30(7):919–927. doi:10.​1002/​mds.​26170 CrossRefPubMedPubMedCentral
go back to reference Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR (2015) The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 9(1):15013. doi:10.1038/npjparkd.2015.13 CrossRef Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR (2015) The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 9(1):15013. doi:10.​1038/​npjparkd.​2015.​13 CrossRef
Metadata
Title
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Authors
Nataliya Titova
Pablo Martinez-Martin
Elena Katunina
K. Ray Chaudhuri
Publication date
01-12-2017
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 12/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-017-1799-3

Other articles of this Issue 12/2017

Journal of Neural Transmission 12/2017 Go to the issue

High Impact Review in Neuroscience, Neurology or Psychiatry - Review Article

Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms